Presentation Information
[C16-05]Modeling clinical trial design considering differences in IC50 between in vitro and in vivo : A case study for COVID-19
*Shotaro Yamamoto1, Taiga Miyazaki2, Shoya Iwanami1, Shingo Iwami1 (1. Nagoya University (Japan), 2. University of Miyazaki (Japan))
Keywords:
Modeling&Simulation,Clinical trials,Drug repurposing,potency reduction factor
Password required to view
The password has been sent to those who have completed payment.